Molecular imaging firm Blue Earth Diagnostics is highlighting several presentations involving its Axumin (fluciclovine F-18) PET radiopharmaceutical and its "radiohybrid" prostate-specific membrane antigen (F-18 rhPSMA-7) imaging agent at the American Urological Association (AUA) annual meeting May 3 to 6 in Chicago.
For fluciclovine F-18, the company touted additional analyses from the LOCATE trial (Impact of F-18 Fluciclovine PET/CT on Management of Patients With Rising PSA After Initial Prostate Cancer Treatment). Researchers delivered an oral presentation describing the sites of suspected recurrent prostate cancer in 213 patients to investigate the potential for fluciclovine F-18 to evaluate oligometastatic disease that's potentially amenable to local treatment. Detection rates on a per-patient basis and by pelvic region were broadly proportional to baseline measurements of prostate-specific antigen (PSA). In addition, 53 (25%) of the patients had oligometastatic disease; 20 (38%) of these subjects had a PSA level ≤ 1.0 ng/mL.
Furthermore, a poster presentation indicated that fluciclovine F-18 detected prostate cancer recurrence in 122 (57%) of the 213 patients. The researchers found that the detection rate was also broadly proportional to the pre-scan PSA level, Blue Earth noted.
Blue Earth said that researchers from Technical University of Munich (TUM) in Germany also shared their initial clinical experience with the investigational F-18 rhPSMA-7 agent in two presentations. In a talk, TUM researchers presented a retrospective analysis that showed 72% sensitivity, 93% specificity, and 86% diagnostic accuracy in a study of 58 patients with high-risk primary prostate cancer.
What's more, a poster presentation involving retrospective analysis of 261 patients showed that F-18 rhPSMA PET/CT yielded an 81% detection rate for biochemically recurrent prostate cancer at a median PSA level of 0.96 ng/ml, the company said.
